Oruka Therapeutics' psoriasis drug meets main goal of mid-stage study
27/04/2026 12:01
April 27 (Reuters) - Oruka Therapeutics ORKA.O said on Monday that interim results showed its experimental psoriasis drug met the main goal of a mid-stage study. (Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar) ((Sneha.SK@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary